Subject(s)
Carcinoma, Renal Cell , Choroid Neoplasms , Kidney Neoplasms , Humans , Kidney Neoplasms/pathology , Kidney Neoplasms/diagnosis , Carcinoma, Renal Cell/secondary , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/diagnosis , Choroid Neoplasms/secondary , Choroid Neoplasms/diagnosis , Male , Middle AgedABSTRACT
We aimed to identify the most appropriate screening strategy for cervical cancer (periodicity of 3, 5 or 10 years) for Tunisia, taking into consideration the incidence of the disease, costs of screening and economic implications. We simulated follow-up of a fictitious cohort of 1 million women 35-39 years over 30 years. Computation of yearly medical care costs was based on data from medical files of patients diagnosed with cervical cancer in 2004 at the National Institute of Cancer, Tunis. For a 60% coverage level of screening, cervical cancer reduction would be 49.2% for a 3-year periodicity. The reduction would be 40.3% and 33.1% for 5 and 10 years periodicity respectively. Considering cost-effectiveness, 10-year screening gave the lowest annual cost to avoid 1 cervical cancer case.
Subject(s)
Mass Screening , Uterine Cervical Neoplasms/diagnosis , Vaginal Smears/economics , Adult , Age Factors , Cost-Benefit Analysis/economics , Direct Service Costs/statistics & numerical data , Female , Follow-Up Studies , Health Planning Guidelines , Humans , Incidence , Mass Screening/economics , Mass Screening/methods , Middle Aged , National Health Programs/economics , Population Surveillance , Registries , Sensitivity and Specificity , Time Factors , Tunisia/epidemiology , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/prevention & controlABSTRACT
We aimed to identify the most appropriate screening strategy for cervical cancer [periodicity of 3, 5 or 10 years] for Tunisia, taking into consideration the incidence of the disease, costs of screening and economic implications. We simulated follow-up of a fictitious cohort of 1 million women 35-39 years over 30 years. Computation of yearly medical care costs was based on data from medical files of patients diagnosed with cervical cancer in 2004 at the National Institute of Cancer, Tunis. For a 60% coverage level of screening, cervical cancer reduction would be 49.2% for a 3-year periodicity. The reduction would be 40.3% and 33.1% for 5 and 10 years periodicity respectively. Considering cost-effectiveness, 10-year screening gave the lowest annual cost to avoid 1 cervical cancer case